Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.35B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
EBITDA Margin
-10195.54%
TTM Avg
-87388.52%
3Y Avg
-48181.08%
5Y Avg
-32386.50%
Market Cap
$1.23B
EBITDA Margin
8.83%
TTM Avg
3.81%
3Y Avg
0.53%
5Y Avg
2.86%
Market Cap
$1.22B
EBITDA Margin
14.64%
TTM Avg
21.61%
3Y Avg
-2.02%
5Y Avg
-22.43%
Market Cap
$1.22B
EBITDA Margin
-2.25%
TTM Avg
-29.69%
3Y Avg
-65.15%
5Y Avg
-190.58%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.33B | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.35B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.37B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -10195.54% | -87388.52% | -48181.08% | -32386.50% |
| Innovage Holding Corp. (INNV)vs › | $1.23B | 8.83% | 3.81% | 0.53% | 2.86% |
| Kardigan, Inc. (KARD)vs › | $1.23B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.22B | 14.64% | 21.61% | -2.02% | -22.43% |
| Cronos Group Inc. (CRON)vs › | $1.22B | -2.25% | -29.69% | -65.15% | -190.58% |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 21.45% | -50.92% | -538.26% | -378.46% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
